Aim ImmunoTech CEO Equels buys $5,093 of common stock

Thomas K. Equels, CEO and President of AIM ImmunoTech Inc. (NASDAQ:AIM), purchased common stock in the company on October 22, 2026.

Mr. Equels acquired 31,250 shares of AIM ImmunoTech common stock at a price of $0.163 per share. The total value of this transaction amounted to $5,093. The purchase comes as the stock trades near its 52-week low of $0.16, with shares down 94% over the past year. Following this direct purchase, Mr. Equels beneficially owns 158,072 shares of the company’s common stock. He also serves as a Director of the company. According to InvestingPro analysis, the stock appears undervalued at current levels, with the company maintaining more cash than debt on its balance sheet. For investors seeking comprehensive insights, InvestingPro offers 13 additional tips and detailed financial metrics to evaluate AIM’s investment potential.

In other recent news, AIM ImmunoTech Inc. has entered into a $1.5 million manufacturing agreement with Sterling Pharma Solutions. This agreement, effective from July 31, 2026, involves the production of additional batches of polynucleotide drug substances, PolyI and Poly C12U, at Sterling’s facility in Dudley, UK. These substances are essential polymer precursors for AIM ImmunoTech’s drug product, Ampligen. The financial commitment will be fulfilled over a 12-month period, as per the agreement’s terms.

Additionally, AIM ImmunoTech’s CEO, Thomas K. Equels, authored an article for Breaking Defense discussing the potential role of Ampligen as a broad-spectrum antiviral therapeutic. The article highlights Ampligen’s potential applications in treating Ebola virus disease and COVID-19, while also noting that preclinical findings are not indicative of FDA approval or clinical efficacy. The company has furnished a copy of this article as an exhibit to the SEC. AIM ImmunoTech emphasized that the article contains forward-looking statements regarding Ampligen’s potential future clinical trials and regulatory submissions.